Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Reckitt Benckiser Group plc (RBGPF)
USD67.35
+0.00 (+0.00%)
GB OTC Consumer Defensive Household & Personal Products
Address
Turner House SL1 3UH
Slough, VIC, GB
Slough, VIC, GB
CEO
Kris Licht
Website
reckitt.com
IPO
2007-11-07
CIK 1420798 ISIN GB00BSZBP530
Also trades on
Deutsche Börse · 3RB.DE (EUR)
London Stock Exchange · RKT.L (GBp)
Other OTC · RBGLY (USD)
Other OTC · RBGPF (USD)
Swiss Exchange · RB.SW (GBP)
Description
Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, and Woolite. It operates through the following segments: Hygiene, Health, and Nutrition. The company was founded by Isaac Reckitt in 1840 and is headquartered in Slough, the United Kingdom.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD67.35
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.8K
Beta
0.25
Float Shares
613.54M
Free Float %
96.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02% | -0.22% | +1.50% | -22.27% | -21.57% | -24.46% | -11.60% | -20.96% | -33.31% | -38.73% | +229.74% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Hold
Price Targets & DCF
Current price
67.35
DCF (Unlevered)
232.93
+245.9%
DCF (Levered)
152.26
+126.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.52
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
7 / 10
Strong MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Household & Personal Products: +3.3%+0.2% Q4'25: +0.9% (vs Q4'23)
-
EPS growth Household & Personal Products: +8.8%+139.9% ★ Q4'25: +508.9% (vs Q4'23)
-
FCF margin FCF growth · Household & Personal Products: +44.8%+20.1% ★ Q4'25: +15.3% (vs Q4'23)
-
EBIT margin Household & Personal Products: +9.9%+29.7% ★ Q4'25: +37.6% (vs Q4'23)
-
ROIC Household & Personal Products: +8.2%+24.7% ★ Q4'25: +67.6% (vs Q4'23)
-
Share dilution Household & Personal Products: +0.2%-7.8% ★ Q4'25: -9.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×1.79× Q4'25: 0.71× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 18 Rev. Ana. 1 EPS Ana. |
Dec 2027 18 Rev. Ana. 1 EPS Ana. |
Dec 2028 8 Rev. Ana. 1 EPS Ana. |
Dec 2029 11 Rev. Ana. 1 EPS Ana. |
Dec 2030 9 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.87B
est: 13.01B (-31.8%)
|
9.89B
est: 12.19B (-18.9%)
|
11.51B
est: 15.66B (-26.5%)
|
12.60B
est: 15.99B (-21.2%)
|
12.85B
est: 17.00B (-24.4%)
|
13.99B
est: 19.13B (-26.8%)
|
13.23B
est: 17.74B (-25.4%)
|
14.45B
est: 17.42B (-17.0%)
|
14.61B
est: 18.78B (-22.2%)
|
14.17B
est: 14.20B (-0.2%)
|
14.20B
est: 14.23B (-0.2%)
|
12.72B
12.26B – 13.03B
-10.6% YoY
|
13.20B
12.99B – 13.45B
+3.8% YoY
|
13.72B
13.37B – 14.02B
+4.0% YoY
|
14.14B
13.78B – 14.45B
+3.0% YoY
|
15.34B
14.95B – 15.67B
+8.5% YoY
|
| EBITDA |
2.42B
est: 2.87B (-15.5%)
|
2.64B
est: 2.69B (-1.9%)
|
2.98B
est: 3.45B (-13.6%)
|
3.48B
est: 3.52B (-1.2%)
|
3.78B
est: 3.74B (+0.9%)
|
2.48B
est: 4.21B (-41.1%)
|
3.02B
est: 3.91B (-22.7%)
|
3.90B
est: 3.84B (+1.7%)
|
3.17B
est: 4.14B (-23.5%)
|
2.96B
est: 5.65B (-47.7%)
|
4.72B
est: 5.66B (-16.7%)
|
5.06B
4.88B – 5.19B
-10.6% YoY
|
5.25B
5.17B – 5.35B
+3.8% YoY
|
5.46B
5.32B – 5.58B
+4.0% YoY
|
5.63B
5.48B – 5.75B
+3.0% YoY
|
6.10B
5.95B – 6.23B
+8.5% YoY
|
| EBIT |
2.25B
est: 2.47B (-8.8%)
|
2.31B
est: 2.31B (-0.4%)
|
2.71B
est: 2.97B (-8.7%)
|
3.07B
est: 3.04B (+1.2%)
|
-1.78B
est: 3.23B (-155.1%)
|
2.15B
est: 3.63B (-40.8%)
|
2.73B
est: 3.37B (-18.9%)
|
3.30B
est: 3.31B (-0.2%)
|
2.71B
est: 3.56B (-24.0%)
|
2.50B
est: 5.06B (-50.7%)
|
4.22B
est: 5.07B (-16.9%)
|
4.53B
4.37B – 4.64B
-10.6% YoY
|
4.71B
4.63B – 4.79B
+3.8% YoY
|
4.89B
4.77B – 5.00B
+4.0% YoY
|
5.04B
4.91B – 5.15B
+3.0% YoY
|
5.47B
5.33B – 5.58B
+8.5% YoY
|
| Net Income |
1.74B
est: 1.71B (+2.0%)
|
1.83B
est: 2.10B (-13.0%)
|
6.17B
est: 2.35B (+162.7%)
|
2.16B
est: 2.19B (-1.4%)
|
-2.77B
est: 2.42B (-214.4%)
|
1.19B
est: 2.32B (-48.8%)
|
-32.00M
est: 2.07B (-101.5%)
|
2.33B
est: 2.41B (-3.5%)
|
1.64B
est: 2.37B (-30.7%)
|
1.43B
est: 2.15B (-33.8%)
|
3.18B
est: 2.37B (+34.5%)
|
2.18B
2.10B – 2.24B
-8.0% YoY
|
2.35B
2.27B – 2.42B
+8.0% YoY
|
2.51B
2.42B – 2.58B
+6.7% YoY
|
2.65B
2.56B – 2.72B
+5.7% YoY
|
2.98B
2.88B – 3.06B
+12.4% YoY
|
| SGA |
2.74B
est: 4.47B (-38.8%)
|
3.11B
est: 4.19B (-25.9%)
|
3.72B
est: 5.39B (-30.9%)
|
4.06B
est: 5.50B (-26.2%)
|
4.16B
est: 5.84B (-28.9%)
|
5.00B
est: 6.58B (-23.9%)
|
4.65B
est: 6.10B (-23.8%)
|
4.64B
est: 5.99B (-22.5%)
|
5.09B
est: 6.46B (-21.3%)
|
4.83B
est: 4.75B (+1.7%)
|
4.42B
est: 4.76B (-7.2%)
|
4.25B
4.10B – 4.36B
-10.6% YoY
|
4.42B
4.35B – 4.50B
+3.8% YoY
|
4.59B
4.47B – 4.69B
+4.0% YoY
|
4.73B
4.61B – 4.83B
+3.0% YoY
|
5.13B
5.00B – 5.24B
+8.5% YoY
|
| EPS |
2.44
est: 2.41 (+1.3%)
|
2.60
est: 2.97 (-12.4%)
|
8.79
est: 3.31 (+165.4%)
|
3.06
est: 3.09 (-0.9%)
|
-3.91
est: 3.42 (-214.4%)
|
1.60
est: 3.27 (-51.0%)
|
-0.09
est: 2.92 (-103.0%)
|
3.27
est: 3.40 (-4.0%)
|
2.27
est: 3.34 (-32.0%)
|
2.04
est: 3.30 (-38.1%)
|
4.88
est: 3.62 (+34.9%)
|
3.33
3.22 – 3.42
-8.0% YoY
|
3.59
3.47 – 3.69
+8.0% YoY
|
3.83
3.71 – 3.94
+6.7% YoY
|
4.05
3.92 – 4.17
+5.7% YoY
|
4.56
4.40 – 4.68
+12.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
3.86B
OE per share TTM
5.61
Owner's Yield
9.42%
Maintenance CapEx ratio
16.53%
Maint CapEx / Avg PPE
16.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
3
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ascot Acquisition Corp. | 100.00 | 100.00% | — | 100.00 | — | 10.00 | CO | Delaware | 2012-12-19 | ↗ |
| 2 | Reckitt Benckiser Group plc | 100.00 | 100.00% | — | 100.00 | — | 10.00 | CO | England and Wales | 2012-12-19 | ↗ |
| 3 | Reckitt Benckiser LLC | 100.00 | 100.00% | — | 100.00 | — | 10.00 | OO | Delaware | 2012-12-19 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
116.5K
Shares Outstanding
637.30M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kristoffer Loe Licht | Chief Executive Officer & Executive Director | 6M | male |
| Shannon Sue Eisenhardt | Chief Financial Officer & Executive Director | 4M | female |
| Catheryn O'Rourke | Senior Vice President, General Counsel & Company Secretary | — | female |
| Jerome Lemaire | President North America | — | male |
| Nicholas James Ashworth | Senior Vice President of Investor Relations | — | male |
| Ranjay Radhakrishnan | Chief Human Resources Officer | — | male |
| Sheila Redzepi | Chief Communications & Corporate Affairs Officer | — | female |
| Alessio Fasano | Chief Science & Medical Officer of Mead Johnson Nutrition (MJN) Business | — | — |
| Susan Sholtis | President of Nutrition | — | female |
| Angela Naef | Chief Research & Development Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RBGPF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
